Rigel Pharmaceuticals, Inc.

0.90 USD
+0.00 (+0.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rigel Pharmaceuticals, Inc. stock is down -0.76% since 30 days ago. The next earnings date is Jul 30, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 23 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 May 18:17 20 Dec, 2024 1.00 PUT 4003 247

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the. treatment of warm autoimmune hemolytic anemia.

  • HC Wainwright & Co.
    Mon Jun 17, 06:16
  • HC Wainwright & Co.
    Mon Jun 3, 12:31